Skip to Content
Merck
All Photos(1)

Key Documents

M0567

Sigma-Aldrich

Microsomes from Liver, Pooled

from human male

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352204
NACRES:
NA.54

biological source

human male

Quality Level

form

liquid

packaging

vial of ~10 mg

shipped in

dry ice

storage temp.

−70°C

Looking for similar products? Visit Product Comparison Guide

Application

Microsomes from Liver, Pooled has been used:
  • in the glucuronidation kinetics assay to test the effects of herbal extracts on glucuronidation process
  • as a human liver microsomes (HLM) matrix for testing metabolic stability of talazoparib using liquid chromatography-tandem mass spectrometry (LC–MS/MS)
  • to study the metabolization of enantiomeric peptide D3

Microsomes from liver have been used in a study to assess differences in enzymatic activities between normal rat livers and from liver after partial hepatectomy. They have also been used in a study to investigate the carbon monoxide-binding pigment in liver microsomes.

Biochem/physiol Actions

Liver microsomes are subcellular particles derived from the endoplasmic reticulum of hepatic cells. These microsomes are a rich source of drug metabolizing enzymes, including cytochrome P-450. Microsome pools from various sources are useful in the study of xenobiotic metabolism and drug interactions.
N-glucuronidation of various 1-substituted imidazoles was found to occur in human liver microsomes.

Storage Class Code

10 - Combustible liquids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Mohamed W Attwa et al.
Drug design, development and therapy, 14, 4439-4449 (2020-10-31)
Tandutinib (MLN518 or CT 53518) (TND) is a novel, oral, small-molecule inhibitor of type III receptor tyrosine kinases utilized for the treatment of acute myeloid leukemia (AML). In silico prediction of hepatic drug metabolism for TND was determined using the
Mohamed W Attwa et al.
Drug design, development and therapy, 14, 111-119 (2020-02-06)
Larotrectinib (VITRAKVI) is an orally potent tropomyosin receptor kinase (Trk) inhibitor that acts by competitive inhibition of all corresponding receptor kinases. It demonstrated a marked response rate (75%) and robust anticancer activity in Trk fusion-positive patients. This response is independent
The enzymatic composition of rat liver microsomes during liver regeneration.
von der DECKEN et al.
Experimental cell research, 19, 591-604 (1960-04-01)
Mohamed W Attwa et al.
Drug design, development and therapy, 15, 3915-3925 (2021-09-24)
Rociletinib (CO-1686; RLC) is a new, small molecule that is orally administered to inhibit mutant-selective covalent inhibitor of most epidermal growth factor receptor (EGFR)-mutated forms, including T790M, L858R, and exon 19 deletions, but not exon 20 insertions. Non-small-cell lung cancer
Mohamed W Attwa et al.
Drug design, development and therapy, 14, 783-793 (2020-03-12)
Talazoparib (BMN673) is a new poly(ADP-ribose) polymerase inhibitor that has been FDA approved for patients suffering from metastatic breast cancer with germline BRCA mutations. In the current study, an accurate and efficient liquid chromatography-tandem mass spectrometry (LC-MS/MS) analytical methodology was

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service